Related Experiment Video
Updated: Sep 3, 2025
13:35
Structural Biology and Analytical Chemistry Approaches for Characterizing C-Glycoside Metabolic Enzymes in Human Gut Microbiota
Published on: May 23, 2025
574
PLG-007 and Its Active Component Galactomannan-α Competitively Inhibit Enzymes That Hydrolyze Glucose Polymers
Michelle C Miller1, Aurelio J Dregni1, David Platt2
1Department of Biochemistry, Molecular Biology & Biophysics, University of Minnesota Health Sciences Center, 6-155 Jackson Hall, 321 Church Street, Minneapolis, MN 55455, USA.
International Journal of Molecular Sciences
|July 27, 2022
Summary
PLG-007, containing GMα, competitively inhibits α-amylase, maltase, and lactase. This mechanism explains how PLG-007 reduces postprandial glucose excursions, offering potential for diabetes and inflammatory disease treatment.
Area of Science:
- Biochemistry
- Pharmacology
- Molecular Biology
Background:
- PLG-007 is a therapeutic compound clinically shown to reduce postprandial glucose excursions.
- It holds potential as an adjunct treatment for diabetes and inflammatory conditions.
- The molecular mechanism of PLG-007 and its galactomannan (GM) components (GMα and GMβ) requires elucidation.
Purpose of the Study:
- To understand the molecular mechanism of action of PLG-007 and its GM components.
- To investigate the inhibitory effects of GMα and GMβ on glucose polymer-hydrolyzing enzymes.
Main Methods:
- Colorimetric assays were employed to assess enzyme inhibition.
- 13C HSQC NMR spectroscopy was utilized to monitor enzyme-mediated hydrolysis.
- Michaelis-Menten kinetic analyses determined inhibition parameters (Vmax, KM, Ki).
Main Results:
- GMα demonstrated significantly stronger inhibition of α-amylase compared to GMβ.
- PLG-007 acts as a competitive inhibitor of α-amylase, maltase, and lactase.
- Kinetic analysis revealed an increase in KM for α-amylase in the presence of PLG-007, indicating competitive inhibition.
Conclusions:
- GMα is the primary active component in PLG-007 responsible for enzyme inhibition.
- PLG-007 competitively inhibits key enzymes involved in glucose metabolism.
- This study provides mechanistic insight into PLG-007's in vivo function for managing glucose levels.
More Related Videos
Related Concept Videos
01:19Oral Hypoglycemic Agents: α-Glucosidase Inhibitors
247
α-glucosidase inhibitors, including acarbose (Precose), miglitol (Glyset), and voglibose (Voglib) (primarily available in Asia), are drugs that control blood sugar levels by delaying the digestion of starch and disaccharides. They achieve this by inhibiting α-glucosidase enzymes in the intestine, which slow the absorption of carbohydrates in the intestine, which in turn leads to a prolonged release of the glucoregulatory hormone GLP-1 from intestinal L-cells.
Acarbose and miglitol are...
Acarbose and miglitol are...
247
01:23Dipeptidyl Peptidase 4 Inhibitors
241
Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...
241
01:24Glucagon-like Receptor Agonists
402
Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
402
01:30Enzyme Inhibition
79.3K
Inhibitors are molecules that reduce enzyme activity by binding to the enzyme. In a normally functioning cell, enzymes are regulated by a variety of inhibitors. Drugs and other toxins can also inhibit enzymes. Some inhibitors bind to the enzyme’s active site, while others inhibit enzymatic activity by binding to other sites on the protein structure.
79.3K
01:06Oral Hypoglycemic Agents: Glinides
243
Repaglinide (Prandin) and Nateglinide (Starlix), known as glinides, are oral insulin secretagogues that stimulate insulin release from pancreatic β cells by closing the ATP-sensitive potassium channels (KATP channel). Repaglinide controls insulin release from pancreatic β cells by managing potassium efflux. It shares two binding sites with sulfonylureas and also has a unique site, indicating overlapping mechanisms of action. With a rapid onset and a 4-7 hour duration, it effectively...
243
01:09GPCRs Regulate Adenylyl Cylase Activity
5.8K
Some GPCRs transmit signals through adenylyl cyclase (AC), a transmembrane enzyme. AC helps synthesize second messenger cyclic adenosine monophosphate (cAMP). AC catalyzes cyclization reaction and converts ATP to cAMP by releasing a pyrophosphate. The pyrophosphate is further hydrolyzed to phosphate by the enzyme pyrophosphatase, which drives cAMP synthesis to completion. However, cAMP is rapidly degraded to 5′ AMP by the enzymes phosphodiesterase (PDE), preventing overstimulation of...
5.8K